The US Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose computed tomography for current and former heavy smokers aged 55 to 80 years. There is little published experience regarding implementing this recommendation in clinical practice.
T he results of the National Lung Screening Trial (NLST), which found a reduction in mortality from lung cancer of 3 deaths per 1000 high-risk individuals screened, 1,2 led to a 2013 US Preventive Services Task Force recommendation   3 in favor of implementing lung cancer screening (LCS) with low-dose computed tomography (LDCT). A process studied in a clinical trial setting, however, may not be directly transferable to real-world clinical practice. The American Academy of Family Physicians cites concerns about the ability to replicate the NLST findings in community practice as a reason not to recommend screening, 4 and primary care physicians and pulmonologists have questioned practical aspects of implementing LCS in practice. 5, 6 Although guidelines about components of high-quality screening programs have been issued, 7-9 published experience with implementation of LCS is limited.
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The Veterans Health Administration (VHA) provides care for 6.7 million mostly older male US veterans each year, 11 many of whom are current or former smokers 12 but who also have multiple medical conditions. 13, 14 Implementation of an LCS program for VHA patients would potentially require substantial resources and effort by clinical staff and facilities for an uncertain benefit of reduced mortality from lung cancer.
To understand the feasibility and implications for VHA patients and clinical staff of programmatic LCS, the VHA implemented a 3-year Lung Cancer Screening Demonstration Project (LCSDP) in 8 geographically diverse hospitals. 15, 16 The specific goals were to describe the organizational effort and resources needed to implement a comprehensive LCS program, patient interest in and acceptance of screening, and the clinical experience of patients who underwent LCS in terms of positive test results, lung cancers detected, and incidental findings. We also wanted to estimate the size of the VHA population that potentially meets eligibility criteria for LCS. This article describes the initial experience of the LCSDP toward these goals.
Methods

Site Selection
The 8 sites, all academic medical centers, were chosen from 35 facilities that volunteered for the demonstration project (eFigure 1 in the Supplement). Selection criteria included having strong support from facility leadership, clinical champions, an onsite CT scanner and radiologist (preferably with training in chest radiology), a multidisciplinary lung cancer program, and a tobacco cessation program.
Project Design and Patient Criteria
The LCSDP was designed as a population-based screening program that proactively identified appropriate patients at the 8 sites for consideration of LCS. First, those aged 55 to 80 years without a diagnosis of esophageal, liver, or pancreatic cancer (following standard VHA protocol) or lung cancer and without a documented estimated life expectancy of fewer than 6 months were identified by an algorithm applied to the VHA electronic medical record. Nurses then reviewed those patients' smoking histories to identify current or former (quit less than 15 years ago) cigarette smokers who had smoked a minimum of 30 pack-years (number of packs per day multiplied by number of years smoked). Based on clinical judgment, patients' primary care professionals excluded those who met initial criteria but who had competing medical conditions that would preclude them from screening (ie, serious comorbid conditions or estimated life expectancy of fewer than 5 years). Patients with documented chest CT scans within the past 12 months were excluded until 12 months had elapsed, as were those with symptoms suggestive of possible lung cancer or those receiving active therapy for cancer other than nonmelanoma skin cancer. Patients without exclusion criteria discussed their interest in undergoing LCS with clinical staff, using a shared decision-making process and brochure (eFigure 2 in the Supplement). 17 Sites were encouraged to start LCS implementation with a small number of interested primary care teams and then expand as resources allowed. One site began screening July 1, 2013; other sites began as they hired clinical LCS coordinators.
Project Materials
Project materials developed for patients and staff are described in detail in eAppendix 1 in the Supplement.AnImplementation Guide provided detailed guidance on a recommended approach to conduct the screening program and included resources, tools, and the evaluation plan. Staff at all sites were encouraged to follow the guidance but were allowed to make changes based on local resources and procedures.
Organizational Effort and Processes
Organizational-level effort and processes reported include brief descriptions of national LCSDP leadership efforts, site leadership activities, and local implementation processes used by the 8 LCSDP screening sites. 
Patient Outcomes
Data Sources
Organizational-level effort data at the 8 sites were collected from internal project notes, telephone calls and email with LCSDP site leaders and coordinators, and monthly site reports. Patient-level data were captured via clinical reminders developed for the project (eAppendix 1 in the Supplement). These electronic tools allowed gathering of data in the medical record that are not recorded using standardized codes (eg, International Classification of Diseases). These data and other standard coded data were obtained from a VHA central data repository. 20 For the estimated number of VHA patients who may be candidates for LCS, VHA central data were used to determine the national number of primary care patients with at least 1 visit to VHA primary care in fiscal year 2014 who met the age and clinical criteria of the cohort eligible for LCS. That number was multiplied by the mean percentage of patients in the project with the appropriate smoking history.
Statistical Analysis
Patients determined to be eligible for LCS as of March 31, 2015, with an initial LDCT scan completed at 1 of the 8 sites by June 30, 2015, are included in these analyses. All patients were followed up through administrative data analysis for 330 days from their initial LDCT scan. They were identified as having confirmed lung cancer if they had at least cations of these events were found within 50 days of the date of the initial LDCT scan (see eAppendix 1 in the Supplement for methodological details about determining initial dates of the LDCT scan). Data were descriptively summarized using counts, percentages, means, and ranges using SAS, version 9.4 (SAS Institute Inc). Cost and budget effect analyses will be reported separately.
Results
Organizational Effort and Processes
Each of the 8 sites named a physician leader (6 pulmonologists, 1 medical oncologist, and 1 radiologist, including K.L.R. and N.T.T.) and hired a full-time LCS clinical coordinator with salary support provided by the VHA (all but 1 were registered nurses or mid-level health care professionals). Coordinators were involved in all daily activities of patient care coordination, including identification of appropriate candidates for screening, delivery of patient education about LCS, participation in shared decision making about screening, scheduling of LDCT scans, notification of patients about results, and follow-up care, as needed, in close collaboration with the physician site leaders. Coordinators were also responsible for educating primary care staff about program procedures. Details about coordinator and site radiologist training and quality assurance review activities are provided in eAppendix 1 in the Supplement. The Implementation Guide was developed, expanded, and revised through frequent conference calls by national LCSDP leadership staff with steering committee members, site leaders, and LCS coordinators. The electronic tools and database were revised multiple times based on input from the coordinators. Patient education materials and guidelines for nodule follow-up were revised to improve clarity and usefulness. Site leaders and coordinators reported variability in how sites implemented their screening programs, especially in terms of identifying patients who met criteria for LCS, which staff engaged in shared decision making with candidates for screening, LCS coordinators' responsibilities, training of primary care staff and radiologists, communicating LCS results with patients, and responsibility for follow-up of incidental findings.
Seven of the 8 sites followed a similar process for offering LCS and obtaining patient agreement (eAppendix 1 the Supplement). At those 7 sites, patients meeting the initial inclusion criteria who were seen by health care professionals participating in the LCSDP were further assessed for eligibility for LCS. Clinicians determined that 4246 of 5035 patients (84.3%) were appropriate for screening (ie, they had no additional medical contraindications). The eighth site mailed patient education materials (the Screening for Lung Cancer brochure [eFigure 2 in the Supplement] 17 ) to patients eligible for LCS and then called them or requested they call the coordinator if interested in discussing LCS further or to request screening.
The 8 sites identified 93 033 patients who met the inclusion and exclusion criteria (Figure) . A total of 36 555 patients (39.3%) were missing information about smoking status or, the tobacco pack-years were improperly calculated; they were not Table 3 ). A total of 73 patients (3.5% of all patients screened) had findings suspicious for possible lung cancer and underwent further diagnostic evaluation. Lung cancer was confirmed for 31 of those patients (1.5%; site range, 0 of 247 to 10 of 444 [2.3%]) within the 330-day follow-up period; 20 (64.5%) of the cancers were stage I ( Table 4 ). The mean number of days from initial LDCT scan to cancer diagnosis was 137 (range, 5-330 days). The remaining 42 patients (2.0%; site range, 0 of 135 to 10 of 247 [4.0%]) who underwent evaluation were not confirmed to have lung cancer during that time frame. The rate of false-positive test results for lung cancer was 97.5% (1226 of 1257) during the 330-day follow-up period (Table 1) .
Yield of Incidental Findings
Radiologists and coordinators were asked to record only incidental findings that would likely require follow-up or further evaluation. Overall, 857 patients (40.7%) had 1 or more incidental findings reported (site range, 89 of 444 [20.0%] to 135 of 213 [63.4%]) (Table 1) . Among the 1044 incidental findings reported, the most common were emphysema, other pulmonary abnormalities, and coronary artery calcification (eTable in the Supplement).
Size of VHA Population That Potentially Meets LCS Eligibility Criteria
Based on the central data analysis described above, we calculated that 2 780 933 primary care VHA patients potentially met the eligibility criteria for visits, age, and medical history. Using the mean of 32% of patients in the demonstration sites who met the additional criteria for smoking history, an estimated 889 899 VHA patients may be candidates for LCS.
Discussion
The VHA LCSDP found implementing a comprehensive LCS program that followed recommendations 7-9 to be challenging and complex, requiring new tools and patient care processes for staff as well as dedicated patient coordination. For example, creating electronic tools to capture the necessary clinical data in real time that met the needs of the LCS coordinators proved to be difficult, even with the VHA's highly a Patients may not have had the opportunity to be assessed for appropriateness of LDCT owing to phased rollout and variability in implementation of tobacco pack-year and initial clinician clinical reminders across LCSDP sites. Presence of clinician assessment was evaluated based on documentation of select health factors in patient record.
b Site 5 used an alternative recruitment process that conducted assessments of appropriateness for screening following preliminary discussions with patients interested in screening.
c Site 5 is not included in this number.
regarded electronic medical record. Although computerized clinical reminders about current or recent smoking are widely used in the VHA, 22 more detailed information about pack-years smoked and years since quitting was required; this information is not fully captured in the electronic medical record.
If the eligibility percentage found in our 8-site project is representative of the VHA population as a whole, we estimate that nearly 900 000 veterans in the VHA health care system would meet the initial screening criteria for age, smoking history, and medical history. Even if this number is reduced by 16%, as found when longer-term medical contraindications were taken into account ( Figure) , the number of veterans who may be candidates for annual LCS is substantial. Accurately identifying these patients and discussing with them the benefits and harms of LCS will take significant effort for primary care teams. Based on LCSDP experience, only about 58% of candidates will agree to be screened. Patients' reasons for declining screening were not collected but may have included concerns about the need for LCS, exposure to radiation, psychological distress, effort required for the screening examinations, and others.
23,24
In addition, performing screening LDCT scans for large numbers of patients may stress the capacity of radiology services, especially considering the number of repeat scans needed, potentially leading to delays for patients needing CT scans for other diagnostic indications. Pulmonary services may also see an increased workload in determining which nodules need follow-up. Finally, primary care will need to be involved in deciding which incidental findings need further evaluation. These clinical efforts will require coordination and communication among clinical services and between patients and staff. Lung cancer screening coordinators will likely be needed to manage population-based LCS programs, leading to additional personnel costs. Such programs will also require training for primary care staff and radiologists, quality assurance measures, and possibly additional CT scanners and radiology staff.
The veterans screened in the VHA demonstration project differed in several ways from the NLST participants. 31 Since only about one-third of nodules identified as needing to be tracked in the LCSDP were 6 mm or greater, the positive rate might decline from nearly 60% to about 20%. However, this possibility assumes that patients with small nodules will continue to be screened annually and any growth will be detected in subsequent scans. Clearer guidance about management of very small nodules is needed, especially for patients who do not continue to be screened. Approximately 40% of those screened in the LCSDP had a variety of incidental findings. Many reported findings, such as emphysema and coronary calcifications, may not require follow-up. However, inclusion of these findings in reports of LDCT scan results requires a health care professional's time to determine if additional testing is necessary.
This clinical demonstration project raises several important questions that warrant further investigation. For example, more needs to be understood about the smoking cessation experience of those who were screened. The study by Zeliadt et al 32 of current smokers who were offered LCS found that screening may negatively influence cessation efforts. We Research Original Investigation Implementation of Lung Cancer Screening in the VHA also need to learn more about the optimal design of decision aids and ways to use shared decision making for LCS. In addition, the significance of and patient experience with incidental findings on results of LDCT scans needs to be further evaluated.
Limitations
These findings have important limitations. Data analysis was based on data in clinical records rather than on data collected by research staff. Missing or incorrectly recorded data about smoking pack-years or years since quitting, for example, were noted for 39.3% of patients who met the initial screening criteria. It is possible that individuals received follow-up care for positive LCS results outside the VHA health care system, and those records would not be available for our analysis. The number of patients treated for lung cancer may be underestimated. Some patients, especially those with significant medical comorbidities who underwent screening, may have received radiation therapy for presumed lung cancer; without diagnosis codes for confirmed lung cancer, those patients were not captured in project data. The follow-up period in this project was less than 1 year; longer follow-up time will be needed to determine the health outcomes of LCS. This project was performed in 8 selected VHA academic medical centers; implementation of LCS programs in smaller medical facilities with fewer resources may differ in many ways. Finally, these findings may not be generalizable to non-VHA health care systems and patients who are not veterans. The experience of the VHA, owing to its central organizational structure, may represent a best-case scenario, but even the VHA was challenged with implementing LCS.
Conclusions
The VHA LCSDP found that a comprehensive LCS program is a complex endeavor for both patients and staff. These results will help the VHA plan for broader implementation of such a program across its health care system and may help other groups considering such screening programs to better understand the multiple components involved and the initial clinical effect on patients.
eAppendix 1. Timeline, Resources, and Methods
Timeline
The VHA's LCSDP was initiated at the request of Under Secretary for Health Robert Petzel in 2012, with funding for 3 years (2012) (2013) (2014) (2015) . The first year was spent planning for the project, selecting the project facilities, developing guidance for implementing the LCS program, and planning the evaluation of the project. Screening began in July 2013 at one of the project sites and continued through September 2015.
Facilities
The 
Resources Developed for VHA Lung Cancer Screening Demonstration Project
A. Implementation Guide: The Implementation Guide, written by the National Center for Health Promotion and Disease Prevention (NCP) and the National Radiology Program Office, with input from the Steering Committee, included information on all project materials listed below, as well as information about smoking cessation resources available in VA medical centers. It was a "live" document throughout the project, with frequent revisions and expansion, based on input from site leaders and LCS coordinators about their experience with implementation processes.
B. Process flow map outlining the clinical steps in a screening program:
The process flow map was developed by NCP, in collaboration with the Pittsburgh Veterans Engineering Resource Center (VERC) and the Steering Committee. The flow map provided a graphical display of each step of the process of lung cancer screening, from identifying appropriate screening candidates to scheduling the LDCTs to following up any findings and scheduling subsequent exams and contacting patients with results. Each demonstration site was encouraged to use the flow map in planning its LCS program and to discuss with relevant clinical services how it would implement each step and who would be responsible for each action.
C. Set of 3 electronic clinical reminders:
Primary care patients who were appropriate for LCS discussion were identified by a set of three clinical reminders developed specifically for the program. Clinical reminders are decision support tools available in the VA's Computerized Patient Record System (CPRS) that prompt staff to screen, review or assess risk factors, or offer services that may be due for an individual patient, based on the patient's age or other factors recorded in the electronic system. Clinical reminders and documentation templates include health factors, computerized components built to capture patient information for which no standard code exists in CPRS. Health factors are created to link specific answers to choices in the reminder/templates. This creates data points to retrieve information from centralized VA data systems (e.g., Corporate Data Warehouse). For the demonstration project, health factors were created or modified by lead project staff and then exported with the reminders or templates and loaded into CPRS at the eight participating sites.
The three clinical reminders were: 1. Tobacco Pack-Year Reminder, which was active only for patients in the target age range for LCS (i.e., ages 55-80 years), who did not have a history of lung, pancreatic, liver or esophageal cancer, did not have a health factor on file indicating a life expectancy of less than 6 months (all permanent exclusions), and had not had a chest CT in the past 12 months (temporary exclusion). Primary care staff completed the reminder by indicating if the patient was a lifetime non-smoker, a former smoker or a current smoker. Former smokers who quit less than 15 years ago and all current smokers were asked how long they smoked and on average, how many cigarettes they smoked each day. A CPRS decision support application used this information to calculate the pack-year history (number of packs smoked per day times the number of years smoked). This reminder was built for the LCSDP since there is not a VHA system-wide smoking reminder and no known local facility smoking reminders that capture pack-year or years since quitting information. The demonstration sites were encouraged to activate this reminder for all Primary Care teams, so that we could obtain an estimate of the total number of Veteran patients who would meet the initial age and smoking history criteria. 2. Initial Lung Cancer Screen (Provider) Reminder, which was completed by providers for patients who met the smoking history criteria (current smoker or former who had quit less than 15 years previously, with 30 pack-years or more of smoking) to indicate if the patients had other clinical exclusions that would not make them good candidates for LCS. "Other clinical exclusions" included symptoms suggestive of lung cancer, estimated life expectancy of less than 5 years or other exclusions determined by provider assessment. If the patient did not have any other exclusions and thus was deemed appropriate for LCS discussion, the provider could choose to: 1) refer the patients to the LCS coordinator for discussion of screening; or 2) continue the process by discussing screening with the patient, documenting the patient's decision concerning screening (to be screened or decline screening for one year or indefinitely) and ordering the LDCT scan for patients who chose to be screened. In addition, patients who were current smokers were asked if they were interested in quitting. Sites could input their local tobacco cessation referrals and prescription medication orders into the reminder if desired. At all sites, patients had the opportunity for tobacco cessation counseling, nicotine replacement therapy, or other medications to assist with tobacco cessation. This reminder was activated only for providers who were actively participating in the LCS process. As noted above, the number of providers offering LCS was intentionally kept small initially and then gradually increased, as sites were ready to expand their programs. 3. Repeat Lung Cancer Screen (Provider) Reminder, which allowed providers to re-assess patients' appropriateness for annual screening on a yearly basis, as long as they continued to meet the age and smoking history criteria. The reminder did not appear for patients who reached the upper age limit or, if former smokers, who reached the 15-year mark since quitting. This reminder was activated only for providers for whom the Initial Provider Reminder was active.
D. Documentation template for site LCS coordinators to record patient information:
The documentation template was an electronic tool in CPRS that allowed coordinators to document patient information about screening process, results, and follow-up. The template consisted of sections that matched patients' flow through the screening process. Coordinators chose the template section that was appropriate to each patient's care and entered his/her clinical information. That process generated health factors that populated the patient tracking tool and were used for nodule follow-up or to trigger clinical reminders for repeat screening.
E. Read-only patient tracking tool/database for coordinators to monitor patients' status in the program:
A tracking tool, a read-only Access database developed by the Pittsburgh VERC, was installed at each of the 8 sites for use by the LCS coordinators to track patients who were being screened, those with nodules, and those undergoing diagnostic evaluation for possible lung cancer. This tool, which was automatically populated based on health factors identifying patients in the LCS program, was designed to support the daily clinical work of the LCS coordinators, providing for them lists of patients in each stage of the screening and follow-up process. The tool was frequently modified by the VERC during the LCSDP, as coordinators identified changes that would better assist them in their daily work. The guide also provided detailed follow-up recommendations for nodules of various sizes and characteristics, to ensure a consistent approach among the 8 sites and multiple radiologists. The nodule follow-up guidelines were based on slightly modified Fleishner Society guidelines (18, 19) , with input from radiology and pulmonary members of the Steering Committee. Laminated copies of the dictation guide/nodule guidelines were distributed to all radiologists at each site who read LDCTs. Participating radiologists received training in these materials through conference calls led by the Chief Consultant for Diagnostic Services. At the conclusion of the project, the guide was extensively re-written to incorporate American College of Radiology lung cancer screening guidelines.
H. Frequently-asked questions document for clinicians:
A "frequently asked questions" document for clinicians was shared with the 8 sites to help them explain the LCSDP to participating clinicians and what it meant for their clinical work.
Training of LCS Coordinators and Site Radiologists
LCS coordinators received two hours of initial training by conference call from NCP staff on the rationale for lung cancer screening; the importance of shared decision-making, including the decision aid and other patient education materials developed for the project; smoking cessation counseling; the use of the clinical reminders, the documentation template, and the patient tracking tool/database; and reporting requirements back to NCP and the evaluation team. Weekly hour-long conference calls were held with the coordinators to answer questions and address issues and problems, as they arose. The NCP Project Coordinator also had calls with individual coordinators as needed for further training and assistance. The coordinators were provided with a set of electronic slides and print materials for use in training primary staff about lung cancer screening and the demonstration project. Training times varied, depending on time available at each site.
Site radiologists received an interpretation guide that defined CT acquisition protocols, how to describe and measure nodules, how to report incidental findings, a dictation format, and treatment recommendations. They also received a summary of the guide to be placed at their workstations. The guide was presented on an initial hour-long conference call; several subsequent conference calls were held to reinforce the guidance and to answer questions.
Quality Assurance Review Activities
To ensure that the LCS coordinators were correctly recording patient information into the documentation template, including transcription of LDCT results, document of follow-up interval when indicated, and documentation of incidental findings, a peer quality assurance process was undertaken in August 2014, about half-way through the LCSDP. In this process, a random sample of 35 patients followed by coordinators at 7 of the 8 sites was selected (the 8 th site
had not yet hired a coordinator). The seven coordinators reviewed clinical information about 5 patients from 5 of the other 6 sites. Each patient's information was sent anonymously and securely to another coordinator for review. Summary and individual coordinator reports were then generated. Overall, documentation was consistent regarding selection of the appropriate section of the coordinator template (97%), documentation of the highest-risk nodule (100%), and notification of findings to patients in a timely manner (96%). Documentation was less consistent for follow-up intervals matching the radiology report (90%), incidental findings (83%), and notifying primary care providers of incidental findings (58%). Some of the lower consistencies for incidental findings and notification of primary care providers concerning incidental findings could be related to the incidental finding already being on the patient's problem list or survey-related issues.
A quality assurance review was also conducted regarding radiologists' interpretations of LDCT and documentation of findings. In August, 2014, a random sample of 63 LDCT scans from each site (8 scans from 6 sites, 9 scans from 1 site and 6 scans from 1 site) was read by a VA radiologist identified by the National Radiology Program who had experience reading LDCT scans for LCS but who was not affiliated with any of the project sites. This radiologist completed an electronic assessment form for each patient. The level of agreement between the radiologist originally reading the scan and the radiologist providing a second read of the scan was then determined. There were potential questions related to adequacy of the image quality for almost half of the scans (47.6%) and appropriate radiation dose (less than 3 mGy) for 39.7% of scans. For 20-25% of the sample, there were clinical differences between impressions of the reviewing radiologist in relation to identification of nodules needing to be tracked and what was reported by the site radiologists. For example, 22.2% of nodules the reviewing radiologist considered needing to be tracked were not indicated as such by the site radiologist. The reviewer did not consider the location of the nodule needing to be tracked to have been reported correctly for 20.6% of nodules, and the diameter was not considered correctly measured by the site radiologist 25.4% of the time. The clinical significance of these differences was not fully assessed; many may have been small differences that would have had minimal clinical impact.
Health Factors and ICD Codes Used
The focus of this article is on the initial round of screening, so only health factors for positive findings (nodules to be tracked and suspicious findings requiring further evaluation) or incidental findings that were recorded within 50 days of the initial screening LDCT were used. The 50-day time frame was chosen based on manual review and counts of the distribution of the dates health factors were entered into CPRS. Health factors entered after that time were not used because they may have been related to surveillance of nodules, rather than screening. Because the time necessary to confirm a lung cancer diagnosis can vary based on a patient's clinical circumstances, codes for lung cancer were searched for up to 330 days (11 months) following the LDCT. A diagnosis of lung cancer is based on a patient having one of the following ICD codes for malignant neoplasm of trachea, bronchus, lung or malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs: ICD-9-CM codes 162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 165.0, 165.8, and 165.9 or ICD-10-CM codes C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C39.0, and C39.9 . Lung cancer cases were confirmed by medical record review for staging and histology.
Determining Initial LDCT and Results Dates
When a patient agreed to lung cancer screening, an electronic order was sent to radiology to conduct an LDCT. On the day of the scheduled radiology appointment, the order was marked as "started," the LDCT was conducted, and then the results were determined by a radiologist. When the report was entered in the medical record, the original order was then marked as "completed." Therefore, for each order placed for an LDCT, both a "started" and "completed" date were typically available. As noted in the Methods section, the initial LDCT date was defined as the completed date for the LDCT order in CPRS. However, there are a variety of scenarios in which the order completion date can be an inaccurate representation of the date on which the initial LDCT actually occurred. For example, there may be no record of an electronic LDCT order (and therefore no order dates), orders may be started but subsequently rescheduled, and radiologists may not always mark orders complete in a timely manner, even though results may have been sent to referring providers. In using administrative medical record data, such scenarios are not unexpected.
There were 104 patients whose initial LDCT completion dates occurred subsequent to at least one of their result dates. Replacing the order completion date with the order start date resolved this discrepancy for 70 of those patients. For the remaining 34 patients for whom this change failed to resolve the discrepancy, full EMR review was performed to determine the date on which the initial LDCT actually occurred and, if applicable, dates on which positive or incidental findings were identified.
Details of Incidental Findings
Radiologists and coordinators were asked to record only those incidental findings that would likely require follow-up or further evaluation. In an effort to minimize data input, they were given broad categories to characterize these findings: abdominal abnormalities; abdominal or thoracic aortic dilation or aneurysm; Infectious, inflammatory, or interstitial process; thyroid nodule; or other incidental findings. Nearly half of the reported findings were reported as "other". This category included a wide variety of findings that were not all well described but most were reported to be emphysema and coronary artery calcifications. We did not collect data on follow-up diagnostic procedures that may have resulted from identification of these findings. 
eTable. Incidental Findings
